NYSE:MRKPharmaceuticals
Merck (NYSE:MRK) Presents Promising KEYTRUDA Trial Data at AACR 2025 Meeting
Merck (NYSE:MRK) recently announced promising results from its Phase 3 KEYNOTE-689 trial of KEYTRUDA, presented at the AACR Annual Meeting, which seems likely to have bolstered investor confidence, contributing to a 6% price increase over the past week. The supplemental Biologics License Application under FDA review further highlights KEYTRUDA's significance in Merck's portfolio. This comes amid a broader market upswing, as the S&P 500 and Nasdaq climbed overall. While Merck's earnings were...